Fujifilm Hldgs Stock Earnings Reports

FUJIFILM reported Q1 FY2026 revenue of JPY749.5 billion and operating income of JPY75.3 billion — both record highs for a Q1 — while net income was JPY53.8 billion (negatively affected by FX losses). On a currency-neutral basis, revenue grew ~4.5% YoY and operating income grew ~35% YoY. Strengths were Bio CDMO (new Denmark facility and ramping US/Texas sites), semiconductor materials (notably CMP slurry), and imaging (instax and digital camera launches). The company confirmed its full-year targets (revenue JPY3.28 trillion; operating income JPY331 billion; net income JPY262 billion) after incorporating an estimated negative operating income impact of JPY6 billion from recent US tariff policy — the company stated this impact was largely mitigated via supply-chain adjustments, pricing and cost measures, and therefore left the prior forecast unchanged (effectively an upward revision). Bio CDMO progress included securing long-term contracts (about USD2 billion total) for Phase 2 US tanks (operational FY2028) and continued order build-up in Denmark. Imaging showed strong product-driven growth and the ability to shift production away from China (Philippines, Japan, SE Asia) to limit tariff exposure. FUJIFILM reiterated sustainability and technology highlights, including a PFAS-free negative-tone ArF immersion photoresist (positive customer evaluations with imec, targeting early market launch). Guidance on risks: FX volatility, geopolitical/inflation uncertainty, and the evolving Chinese medical-film market were called out; management is pursuing market diversification (India, Middle East, Central Asia, Africa) and operational levers to capture upside.